Vascular Surgery Group, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Br J Surg. 2013 Jun;100(7):863-72. doi: 10.1002/bjs.9101. Epub 2013 Mar 8.
Any possible long-term benefit from endovascular (EVAR) versus open surgical repair for abdominal aortic aneurysm (AAA) remains unproven. Long-term data from the Open Versus Endovascular Repair (OVER) trial add to the debate regarding long-term all-cause and aneurysm-related mortality. The aim of this study was to investigate 30-day and long-term mortality, reintervention, rupture and morbidity after EVAR and open repair for AAA in a systematic review.
Standard PRISMA guidelines were followed. Random-effects Mantel-Haenszel meta-analysis was performed to evaluate mortality and morbidity outcomes.
The existing published randomized trials, together with information from Medicare and SwedVasc databases, were included in a meta-analysis. This included 25 078 patients undergoing EVAR and 27 142 undergoing open repair for AAA. Patients who had EVAR had a significantly lower 30-day or in-hospital mortality rate (1·3 per cent versus 4·7 per cent for open repair; odds ratio (OR) 0·36, 95 per cent confidence interval 0·21 to 0·61; P < 0·001). By 2-year follow-up there was no difference in all-cause mortality (14·3 versus 15·2 per cent; OR 0·87, 0·72 to 1·06; P = 0·17), which was maintained after at least 4 years of follow-up (34·7 versus 33·8 per cent; OR 1·11, 0·91 to 1·35; P = 0·30). There was no significant difference in aneurysm-related mortality by 2 years or longer follow-up. A significantly higher proportion of patients undergoing EVAR required reintervention (P = 0·003) and suffered aneurysm rupture (P < 0·001).
There is no long-term survival benefit for patients who have EVAR compared with open repair for AAA. There are also significantly higher risks of reintervention and aneurysm rupture after EVAR.
血管内(EVAR)与开放手术修复腹主动脉瘤(AAA)的长期获益仍未得到证实。来自开放与血管内修复(OVER)试验的长期数据增加了关于长期全因和动脉瘤相关死亡率的争论。本研究旨在通过系统评价调查 EVAR 和开放修复 AAA 后 30 天和长期死亡率、再干预、破裂和发病率。
遵循标准 PRISMA 指南。采用随机效应 Mantel-Haenszel 荟萃分析评估死亡率和发病率结果。
本 meta 分析纳入了已发表的随机试验以及 Medicare 和 SwedVasc 数据库的信息,共包括 25078 例行 EVAR 和 27142 例行开放修复的 AAA 患者。EVAR 组的 30 天或住院内死亡率显著较低(1.3%比开放修复组的 4.7%;比值比[OR] 0.36,95%置信区间 0.21 至 0.61;P<0.001)。在 2 年随访时,全因死亡率无差异(14.3%比 15.2%;OR 0.87,0.72 至 1.06;P=0.17),且在至少 4 年随访后仍保持(34.7%比 33.8%;OR 1.11,0.91 至 1.35;P=0.30)。2 年或更长时间的随访时,动脉瘤相关死亡率无显著差异。EVAR 组需要再次干预的患者比例显著更高(P=0.003),且动脉瘤破裂的风险更高(P<0.001)。
与开放修复相比,EVAR 治疗 AAA 患者没有长期生存获益。EVAR 后再干预和动脉瘤破裂的风险也显著更高。